Application of Individual Case Management Nursing Model in Blood Lipid Management of Patients with Coronary Heart Disease

Zheng Xie; Yanqiu Xie

doi:10.62051/ijphmr.v2n1.17

Authors

Zheng Xie
Yanqiu Xie

DOI:

https://doi.org/10.62051/ijphmr.v2n1.17

Keywords:

Case management model, Coronary heart disease, Hyperlipidemia, Medication adherence

Abstract

Objective: To explore the effect of the case management nursing model on lipid management in patients with coronary heart disease. Methods: Coronary heart disease patients admitted to the cardiology department of a tertiary hospital in Henan Province from April 2023 to March 2024 were randomly divided into a conventional care group and a case management group. The case management model was implemented, and a 3-month follow-up was conducted. Data were collected and analyzed. Results: There were no statistically significant differences in baseline data between the two groups. After 3 months of case management, the case management group showed better medication adherence, greater reductions in lipid levels, and higher lipid control rates. Conclusion: The case management nursing model can improve medication adherence and lipid control rates in patients with coronary heart disease.

References

[1] Zhu Junren, Gao Runlin, Zhao Shuiping, et al. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016 revised edition) [J]. Chinese Journal of Circulation, 2016, 31(10): 937-953. DOI: 10.3969/j.issn.1000-3614.2016.10.001

[2] Andrew M, Dongfeng G, Dong Z, et al. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. [J]. Circulation. Cardiovascular quality and outcomes, 2010, 3 (3). DOI:10.1161/CIRCOUTCOMES.109.910711

[3] Gitt A K, Lautsch D, Ferrières J, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II [J]. Atherosclerosis, 2017, 266:158-166. DOI:10.1016/j.atherosclerosis. 2017.08.013

[4] Low W C, Hess C N, Hiatt W R, et al. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations [J]. Circulation, 2016, 133(24):2459-2502. DOI:10.1161/CIRCULATIONAHA.116.022194

[5] Ji H, Chen R, Huang Y, et al. Effect of simulation education and case management on glycemic control in type 2 diabetes [J]. Diabetes Metab Res Rev, 2019, 35(3):e3112. DOI:10.1002/dmrr. 3112

[6] Takeda A, Martin N, Taylor R S, et al. Disease management interventions for heart failure [J]. Cochrane Database Syst Rev, 2019, 1(1):D2752. DOI:10.1002/14651858.CD002752.pub4

[7] Hudon C, Chouinard M C, Dubois M F, et al. Case Management in Primary Care for Frequent Users of Health Care Services: A Mixed Methods Study [J]. Ann Fam Med, 2018, 16(3):232-239. DOI:10.1370/afm.2233

[8] Egede L E, Williams J S, Voronca D C, et al. Randomized Controlled Trial of Technology-Assisted Case Management in Low Income Adults with Type 2 Diabetes [J]. Diabetes Technol Ther, 2017, 19(8):476-482. DOI:10.1089/dia.2017.0006

[9] Morisky D E, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting [J]. J Clin Hypertens (Greenwich), 2008, 10(5):348-354. DOI:10.1111/j.1751-7176.2008.07572.x

[10] Chiang C Y, Choi K C, Ho K M, et al. Effectiveness of nurse-led patient-centered care behavioral risk modification on secondary prevention of coronary heart disease: A systematic review [J]. Int J Nurs Stud, 2018, 84:28-39. DOI:10.1016/j.ijnurstu.2018.04.012

[11] Satija A, Bhupathiraju S N, Spiegelman D, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults [J]. J Am Coll Cardiol, 2017, 70(4):411-422. DOI:10.1016/j.jacc.2017.05.047

[12] Wood D A, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial [J]. Lancet, 2008, 371(9629):1999-2012. DOI:10.1016/S0140-6736(08)60868-5

[13] Cannon C P, Khan I, Klimchak A C, et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease [J]. JAMA Cardiol, 2017, 2(9):959-966. DOI:10.1001/jamacardio.2017.2289

[14] Daida H, Dohi T, Fukushima Y, et al. The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials [J]. J Atheroscler Thromb, 2019, 26(7):592-600. DOI:10.5551/jat.48603

[15] Goldberg A C, Leiter L A, Stroes E, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial [J]. JAMA, 2019, 322(18):1780-1788. DOI:10.1001/jama.2019.20661